Key Takeaway: Nurix has reported that its IRAK4 degrader GS-6791 effectively inhibits TLR and IL-1R-driven inflammatory signaling. This compound has shown the ability to ameliorate disease symptoms in a preclinical model of arthritis. The findings suggest a potential new avenue for treating autoimmune diseases.
Price reaction · baseline $26.86 (2024-11-14 close) · hit pre-market · 3 other NRIX headline(s) in the window, move may be shared
day 0 close
-14.7%
day 1 · peak
-18.9%
day 3
-15.7%
Market Sentiment Analysis
POSITIVE FACTORS
GS-6791 shows promise in inhibiting inflammatory signaling.
The study demonstrates potential therapeutic benefits in arthritis.
Nurix is advancing its innovative multi-modal portfolio.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is GS-6791?
GS-6791 is an IRAK4 degrader developed by Nurix that targets inflammatory signaling.
How does GS-6791 affect arthritis?
In preclinical studies, GS-6791 has been shown to ameliorate symptoms of arthritis.
What pathways does GS-6791 inhibit?
GS-6791 inhibits TLR and IL-1R-driven inflammatory signaling pathways.
What is Nurix's focus?
Nurix is focused on developing therapies for cancer and autoimmune diseases.